Roivant Sciences (ROIV)
Roivant Sciences on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
40.3M
Short interest
settlement 2026-10-15
7.9
Days to cover
+3.5 days vs prior
80.8%
Short share of volume
2026-10-28
719
Fails to deliver
settlement 2026-09-28
Mon 9 Nov
Next earnings
estimated date
-$59.9M
Insider flow, 90 days
0 buys, 19 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ROIV is 40,302,998 shares, up 4,121,450 shares over the last month. Over the last 48 readings it ranged from 17,520,355 shares (15 December 2025) to 52,735,015 shares (30 April 2025). At the reported average volume of 5.1M shares a day that is 7.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/roiv" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 40,302,998 | +2.6% | 5,110,326 | 7.89 |
| 2026-09-30 | 39,296,630 | +8.6% | 8,877,408 | 4.43 |
| 2026-09-15 | 36,181,548 | +7.9% | 8,751,820 | 4.13 |
| 2026-08-31 | 33,522,300 | +9.5% | 8,757,588 | 3.83 |
| 2026-08-14 | 30,601,726 | -13.2% | 6,103,989 | 5.01 |
| 2026-07-31 | 35,233,818 | -4.0% | 4,407,819 | 7.99 |
| 2026-07-15 | 36,695,558 | +10.5% | 4,798,919 | 7.65 |
| 2026-06-30 | 33,212,917 | -0.1% | 7,782,780 | 4.27 |
| 2026-06-15 | 33,244,439 | -8.3% | 4,423,546 | 7.52 |
| 2026-05-29 | 36,233,835 | +32.4% | 8,748,838 | 4.14 |
| 2026-05-15 | 27,377,524 | +1.2% | 4,807,466 | 5.69 |
| 2026-04-30 | 27,055,375 | +10.6% | 5,595,903 | 4.83 |
| 2026-04-15 | 24,470,022 | -1.7% | 4,229,831 | 5.79 |
| 2026-03-31 | 24,884,496 | +6.4% | 5,793,424 | 4.30 |
| 2026-03-13 | 23,387,772 | -0.3% | 6,440,939 | 3.63 |
| 2026-02-27 | 23,457,731 | +5.3% | 4,598,282 | 5.10 |
| 2026-02-13 | 22,266,323 | -4.4% | 9,170,829 | 2.43 |
| 2026-01-30 | 23,288,019 | -5.1% | 4,582,244 | 5.08 |
| 2026-01-15 | 24,529,353 | +25.3% | 6,681,612 | 3.67 |
| 2025-12-31 | 19,579,958 | +11.8% | 7,948,165 | 2.46 |
| 2025-12-15 | 17,520,355 | -16.2% | 7,915,441 | 2.21 |
| 2025-11-28 | 20,914,523 | -9.3% | 5,699,020 | 3.67 |
| 2025-11-14 | 23,049,893 | -6.0% | 9,547,574 | 2.41 |
| 2025-10-31 | 24,528,207 | -2.9% | 8,812,288 | 2.78 |
| 2025-10-15 | 25,271,869 | -9.6% | 6,660,670 | 3.79 |
| 2025-09-30 | 27,966,982 | -22.8% | 9,744,740 | 2.87 |
| 2025-09-15 | 36,208,272 | -7.3% | 9,353,784 | 3.87 |
| 2025-08-29 | 39,048,414 | +2.5% | 4,041,413 | 9.66 |
| 2025-08-15 | 38,087,315 | -0.6% | 5,013,746 | 7.60 |
| 2025-07-31 | 38,312,269 | -9.6% | 4,142,598 | 9.25 |
| 2025-07-15 | 42,356,220 | +3.1% | 7,537,150 | 5.62 |
| 2025-06-30 | 41,098,083 | -8.8% | 8,117,786 | 5.06 |
| 2025-06-13 | 45,062,132 | +1.4% | 5,317,892 | 8.47 |
| 2025-05-30 | 44,430,557 | -9.8% | 4,590,442 | 9.68 |
| 2025-05-15 | 49,232,094 | -6.6% | 5,774,501 | 8.53 |
| 2025-04-30 | 52,735,015 | +2.9% | 5,891,949 | 8.95 |
| 2025-04-15 | 51,228,016 | +13.6% | 8,976,081 | 5.71 |
| 2025-03-31 | 45,101,301 | -13.4% | 8,237,686 | 5.47 |
| 2025-03-14 | 52,088,746 | +12.9% | 5,534,137 | 9.41 |
| 2025-02-28 | 46,137,518 | +8.8% | 4,241,130 | 10.88 |
| 2025-02-14 | 42,397,092 | +0.5% | 4,456,585 | 9.51 |
| 2025-01-31 | 42,195,273 | -6.0% | 3,353,810 | 12.58 |
| 2025-01-15 | 44,880,714 | +3.2% | 4,930,094 | 9.10 |
| 2024-12-31 | 43,500,273 | -1.6% | 5,493,863 | 7.92 |
| 2024-12-13 | 44,198,382 | -7.5% | 3,945,622 | 11.20 |
| 2024-11-29 | 47,806,109 | +10.3% | 5,303,525 | 9.01 |
| 2024-11-15 | 43,348,974 | -6.9% | 4,991,448 | 8.68 |
| 2024-10-31 | 46,572,879 | -7.2% | 3,265,006 | 14.26 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of ROIV volume is 80.8%, up 22.0 points over the last five sessions. Over the last 30 readings it ranged from 42.2% (17 September 2026) to 80.8% (28 October 2026). The latest reading sits at the top of that range. The latest reading is 18.9 points above the 30-session average of 61.9%, on 1.6M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 1.3M | 1.6M | 80.8% | 12,640 |
| 2026-10-27 | 1.7M | 3.8M | 44.8% | 6,356 |
| 2026-10-26 | 1.7M | 3.7M | 45.8% | 1 |
| 2026-10-23 | 1.6M | 3.7M | 44.1% | 7,001 |
| 2026-10-22 | 4.7M | 6.5M | 72.3% | 53,455 |
| 2026-10-21 | 4.3M | 7.4M | 58.8% | 11,235 |
| 2026-10-20 | 876K | 1.6M | 56.2% | 135,772 |
| 2026-10-19 | 1.7M | 2.5M | 67.2% | 5,175 |
| 2026-10-16 | 1.2M | 1.8M | 67.2% | 106 |
| 2026-10-15 | 1.2M | 1.6M | 74.9% | 22 |
| 2026-10-14 | 806K | 1.3M | 62.0% | 0 |
| 2026-10-13 | 802K | 1.4M | 56.6% | 3,002 |
| 2026-10-12 | 874K | 1.8M | 48.2% | 2,008 |
| 2026-10-09 | 1.3M | 2.0M | 67.4% | 10 |
| 2026-10-08 | 1.4M | 2.1M | 69.2% | 8,922 |
| 2026-10-07 | 1.5M | 2.1M | 71.2% | 0 |
| 2026-10-06 | 1.5M | 2.1M | 69.2% | 3 |
| 2026-10-05 | 954K | 1.4M | 68.2% | 303 |
| 2026-10-02 | 867K | 1.2M | 73.3% | 170 |
| 2026-10-01 | 719K | 1.1M | 66.4% | 1,622 |
| 2026-09-30 | 1.1M | 1.4M | 77.3% | 122,234 |
| 2026-09-29 | 1.3M | 1.8M | 70.9% | 21,565 |
| 2026-09-28 | 1.7M | 2.2M | 80.0% | 758 |
| 2026-09-25 | 1.6M | 2.6M | 63.4% | 514 |
| 2026-09-24 | 1.1M | 2.1M | 54.1% | 10,299 |
| 2026-09-23 | 1.4M | 2.4M | 55.8% | 365 |
| 2026-09-22 | 874K | 2.1M | 42.4% | 508 |
| 2026-09-21 | 929K | 1.9M | 48.3% | 56 |
| 2026-09-18 | 2.1M | 3.6M | 58.1% | 389 |
| 2026-09-17 | 1.3M | 3.1M | 42.2% | 6,365 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 28 September 2026, the fails-to-deliver balance in ROIV is 719 shares, down 205 shares over the last settlement date. Over the last 30 readings it ranged from 9 shares (27 April 2026) to 1,399,610 shares (20 February 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-28 | 719 | $35.80 | $26K |
| 2026-09-25 | 924 | $36.13 | $33K |
| 2026-09-17 | 31 | $39.57 | $1K |
| 2026-09-16 | 36,030 | $39.50 | $1.4M |
| 2026-09-15 | 5,293 | $41.02 | $217K |
| 2026-09-11 | 5,306 | $40.94 | $217K |
| 2026-09-10 | 49,163 | $41.81 | $2.1M |
| 2026-09-09 | 102,373 | $41.48 | $4.2M |
| 2026-08-21 | 2,028 | $36.84 | $75K |
| 2026-08-20 | 127 | $37.40 | $5K |
| 2026-06-30 | 575 | $34.73 | $20K |
| 2026-06-29 | 448,710 | $34.07 | $15.3M |
| 2026-06-22 | 2,227 | $31.43 | $70K |
| 2026-06-15 | 12,109 | $30.04 | $364K |
| 2026-06-08 | 30,276 | $28.58 | $865K |
| 2026-06-01 | 38,910 | $29.99 | $1.2M |
| 2026-05-28 | 56,175 | $29.58 | $1.7M |
| 2026-05-26 | 2,206 | $29.96 | $66K |
| 2026-05-18 | 150 | $29.29 | $4K |
| 2026-05-13 | 379 | $29.39 | $11K |
| 2026-04-27 | 9 | $27.41 | $247 |
| 2026-04-17 | 612,895 | $29.19 | $17.9M |
| 2026-04-06 | 668 | $28.33 | $19K |
| 2026-03-31 | 122 | $26.41 | $3K |
| 2026-03-26 | 266 | $27.36 | $7K |
| 2026-03-25 | 49 | $26.87 | $1K |
| 2026-03-23 | 28 | $27.70 | $776 |
| 2026-03-03 | 2,411 | $28.10 | $68K |
| 2026-02-23 | 1,055,638 | $27.15 | $28.7M |
| 2026-02-20 | 1,399,610 | $27.52 | $38.5M |
Insider trades
SEC Form 4, newest first. JSONInsiders at ROIV reported 19 open-market sells worth $59.9M in the last 90 days and no open-market buys. Latest filing: MOMTAZEE JAMES C (Director) on 2026-10-23.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-23 | MOMTAZEE JAMES C | Director | Tax withholding | 77 | $36.49 | $3K | 112K |
| 2026-10-23 | MOMTAZEE JAMES C | Director | Grant | 383 | $0.00 | $0 | 112K |
| 2026-10-23 | Epperly Melissa B, | Director | Tax withholding | 116 | $36.49 | $4K | 15K |
| 2026-10-23 | Epperly Melissa B, | Director | Grant | 513 | $0.00 | $0 | 15K |
| 2026-10-23 | Oren Ilan | Director | Grant | 810 | $0.00 | $0 | 124K |
| 2026-10-20 | Venker Eric | President & Immunovant CEO | Sell | 14K | $35.42 | $501K | 1.4M |
| 2026-10-20 | Venker Eric | President & Immunovant CEO | Sell | 186K | $35.09 | $6.5M | 1.4M |
| 2026-10-16 | Gline Matthew | CEO | Tax withholding | 35K | $33.53 | $1.2M | 16.5M |
| 2026-10-16 | Sukhatme Mayukh | President & CIO | Tax withholding | 20K | $33.53 | $670K | 18.6M |
| 2026-10-01 | Epperly Melissa B, | Director | Sell | 900 | $36.57 | $33K | 15K |
| 2026-10-01 | Epperly Melissa B, | Director | Sell | 17K | $36.08 | $608K | 16K |
| 2026-10-01 | Epperly Melissa B, | Director | Exercise or conversion | 18K | $4.46 | $79K | 33K |
| 2026-09-30 | Sukhatme Mayukh | President & CIO | Tax withholding | 47K | $36.57 | $1.7M | 18.6M |
| 2026-09-30 | Venker Eric | President & Immunovant CEO | Sell | 200K | $36.62 | $7.3M | 1.6M |
| 2026-09-30 | Venker Eric | President & Immunovant CEO | Exercise or conversion | 200K | $3.85 | $770K | 1.8M |
| 2026-09-30 | Torti Frank | President and Vant Chair | Tax withholding | 40K | $36.57 | $1.5M | 13.5M |
| 2026-09-30 | Gline Matthew | CEO | Tax withholding | 76K | $36.57 | $2.8M | 16.6M |
| 2026-09-20 | Humes Jennifer | Chief Accounting Officer | Tax withholding | 4K | $39.77 | $154K | 106K |
| 2026-09-20 | Pulik Richard | CFO | Tax withholding | 2K | $39.77 | $85K | 270K |
| 2026-09-16 | MANCHESTER KEITH S | Director | Grant | 5K | $0.00 | $0 | 1.8M |
| 2026-09-16 | MOMTAZEE JAMES C | Director | Grant | 5K | $0.00 | $0 | 112K |
| 2026-09-16 | Oren Ilan | Director | Grant | 5K | $0.00 | $0 | 124K |
| 2026-09-16 | Gold Daniel Allen | Director | Grant | 5K | $0.00 | $0 | 9.0M |
| 2026-09-16 | Epperly Melissa B, | Director | Grant | 5K | $0.00 | $0 | 15K |
| 2026-09-16 | Fitzgerald Meghan | Director | Grant | 5K | $0.00 | $0 | 41K |
| 2026-09-15 | Fitzgerald Meghan | Director | Sell | 400 | $40.45 | $16K | 36K |
| 2026-09-15 | Fitzgerald Meghan | Director | Sell | 5K | $39.68 | $187K | 37K |
| 2026-09-15 | Epperly Melissa B, | Director | Sell | 600 | $40.38 | $24K | 10K |
| 2026-09-15 | Epperly Melissa B, | Director | Sell | 4K | $39.65 | $172K | 11K |
| 2026-09-10 | Gold Daniel Allen | Director | Tax withholding | 5K | $40.94 | $210K | 9.0M |
| 2026-09-10 | Epperly Melissa B, | Director | Tax withholding | 2K | $40.94 | $89K | 15K |
| 2026-09-10 | Oren Ilan | Director | Tax withholding | 2K | $40.94 | $97K | 119K |
| 2026-09-10 | MOMTAZEE JAMES C | Director | Tax withholding | 3K | $40.94 | $119K | 107K |
| 2026-09-10 | Fitzgerald Meghan | Director | Tax withholding | 2K | $40.94 | $71K | 41K |
| 2026-09-08 | Fitzgerald Meghan | Director | Sell | 20K | $39.90 | $798K | 43K |
| 2026-09-08 | Fitzgerald Meghan | Director | Exercise or conversion | 20K | $8.80 | $176K | 63K |
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Sell | 34K | $36.44 | $1.2M | 1.6M |
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Sell | 166K | $35.63 | $5.9M | 1.6M |
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Exercise or conversion | 200K | $3.85 | $770K | 1.8M |
| 2026-08-21 | Sukhatme Mayukh | President & CIO | Sell | 145K | $36.48 | $5.3M | 18.6M |
| 2026-08-21 | Sukhatme Mayukh | President & CIO | Exercise or conversion | 145K | $3.85 | $557K | 18.8M |
| 2026-08-20 | Venker Eric | President & Immunovant CEO | Tax withholding | 14K | $36.84 | $512K | 1.6M |
| 2026-08-20 | Pulik Richard | CFO | Tax withholding | 6K | $36.84 | $212K | 272K |
| 2026-08-20 | Sukhatme Mayukh | President & CIO | Sell | 18K | $37.30 | $653K | 18.6M |
| 2026-08-20 | Sukhatme Mayukh | President & CIO | Exercise or conversion | 18K | $3.85 | $67K | 18.6M |
| 2026-08-19 | Sukhatme Mayukh | President & CIO | Sell | 173K | $37.17 | $6.4M | 18.6M |
| 2026-08-19 | Sukhatme Mayukh | President & CIO | Exercise or conversion | 173K | $3.85 | $666K | 18.8M |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Sell | 32K | $37.18 | $1.2M | 18.6M |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Exercise or conversion | 32K | $3.85 | $122K | 18.7M |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Sell | 105K | $36.59 | $3.8M | 18.6M |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Exercise or conversion | 105K | $3.85 | $405K | 18.7M |
| 2026-08-17 | Sukhatme Mayukh | President & CIO | Sell | 285K | $36.25 | $10.3M | 18.6M |
| 2026-08-17 | Sukhatme Mayukh | President & CIO | Exercise or conversion | 285K | $3.85 | $1.1M | 18.9M |
| 2026-08-14 | Sukhatme Mayukh | President & CIO | Sell | 243K | $36.23 | $8.8M | 18.6M |
| 2026-08-14 | Sukhatme Mayukh | President & CIO | Exercise or conversion | 243K | $3.85 | $936K | 18.9M |
| 2026-07-27 | Venker Eric | President & Immunovant CEO | Sell | 200K | $34.95 | $7.0M | 1.6M |
| 2026-07-27 | Venker Eric | President & Immunovant CEO | Exercise or conversion | 200K | $3.85 | $770K | 1.8M |
| 2026-07-17 | Oren Ilan | Director | Grant | 775 | $0.00 | $0 | 121K |
| 2026-07-17 | MOMTAZEE JAMES C | Director | Grant | 405 | $0.00 | $0 | 110K |
| 2026-07-17 | Epperly Melissa B, | Director | Grant | 543 | $0.00 | $0 | 17K |
| 2026-06-30 | Torti Frank | President and Vant Chair | Tax withholding | 40K | $35.39 | $1.4M | 13.5M |
| 2026-06-30 | Sukhatme Mayukh | President & CIO | Tax withholding | 47K | $35.39 | $1.7M | 18.6M |
| 2026-06-30 | Gline Matthew | CEO | Tax withholding | 76K | $35.39 | $2.7M | 16.7M |
| 2026-06-30 | Fitzgerald Meghan | Director | Sell | 10K | $34.90 | $349K | 43K |
| 2026-06-30 | Fitzgerald Meghan | Director | Exercise or conversion | 10K | $8.80 | $88K | 53K |
| 2026-06-30 | QVT Financial LP | Other | Sell | 12K | $35.28 | $437K | 13.7M |
| 2026-06-30 | Gold Daniel Allen | Director | Sell | 12K | $35.28 | $437K | 13.7M |
| 2026-06-30 | MANCHESTER KEITH S | Director | Sell | 12K | $35.28 | $437K | 13.7M |
| 2026-06-30 | MANCHESTER KEITH S | Director | Sell | 200K | $35.45 | $7.1M | 1.7M |
| 2026-06-29 | Epperly Melissa B, | Director | Sell | 3K | $34.71 | $95K | 16K |
| 2026-06-29 | Epperly Melissa B, | Director | Sell | 15K | $34.32 | $515K | 19K |
| 2026-06-29 | Epperly Melissa B, | Director | Exercise or conversion | 18K | $4.46 | $79K | 34K |
| 2026-06-29 | QVT Financial LP | Other | Sell | 200K | $34.44 | $6.9M | 14.3M |
| 2026-06-29 | QVT Financial LP | Other | Sell | 600K | $34.59 | $20.8M | 13.7M |
| 2026-06-29 | Gold Daniel Allen | Director | Sell | 600K | $34.59 | $20.8M | 13.7M |
| 2026-06-29 | Gold Daniel Allen | Director | Sell | 200K | $34.44 | $6.9M | 14.3M |
| 2026-06-29 | MANCHESTER KEITH S | Director | Sell | 200K | $34.44 | $6.9M | 14.3M |
| 2026-06-29 | MANCHESTER KEITH S | Director | Sell | 600K | $34.59 | $20.8M | 13.7M |
| 2026-06-26 | Sukhatme Mayukh | President & CIO | Sell | 500K | $34.08 | $17.0M | 18.7M |
| 2026-06-26 | Sukhatme Mayukh | President & CIO | Exercise or conversion | 500K | $3.85 | $1.9M | 19.2M |
| 2026-06-26 | QVT Financial LP | Other | Sell | 301K | $33.92 | $10.2M | 14.8M |
| 2026-06-26 | QVT Financial LP | Other | Sell | 325K | $34.07 | $11.1M | 14.5M |
| 2026-06-26 | Gold Daniel Allen | Director | Sell | 301K | $33.92 | $10.2M | 14.8M |
| 2026-06-26 | Gold Daniel Allen | Director | Sell | 325K | $34.07 | $11.1M | 14.5M |
| 2026-06-26 | MANCHESTER KEITH S | Director | Sell | 301K | $33.92 | $10.2M | 14.8M |
| 2026-06-26 | MANCHESTER KEITH S | Director | Sell | 325K | $34.07 | $11.1M | 14.5M |
| 2026-06-25 | Sukhatme Mayukh | President & CIO | Sell | 500K | $34.13 | $17.1M | 18.7M |
| 2026-06-25 | Sukhatme Mayukh | President & CIO | Exercise or conversion | 500K | $3.85 | $1.9M | 19.2M |
| 2026-06-24 | Venker Eric | President & Immunovant CEO | Exercise or conversion | 200K | $3.85 | $770K | 1.8M |
| 2026-06-24 | Venker Eric | President & Immunovant CEO | Sell | 154K | $33.05 | $5.1M | 1.7M |
| 2026-06-24 | Venker Eric | President & Immunovant CEO | Sell | 46K | $33.51 | $1.5M | 1.6M |
| 2026-06-20 | Humes Jennifer | Chief Accounting Officer | Tax withholding | 4K | $31.43 | $113K | 110K |
| 2026-06-20 | Pulik Richard | CFO | Tax withholding | 2K | $31.43 | $67K | 276K |
| 2026-05-22 | Venker Eric | President & Immunovant CEO | Sell | 200K | $30.27 | $6.1M | 1.6M |
| 2026-05-22 | Venker Eric | President & Immunovant CEO | Exercise or conversion | 200K | $3.85 | $770K | 1.8M |
| 2026-05-20 | Venker Eric | President & Immunovant CEO | Tax withholding | 34K | $32.41 | $1.1M | 1.6M |
| 2026-05-20 | Pulik Richard | CFO | Tax withholding | 19K | $32.41 | $615K | 279K |
| 2026-04-20 | Venker Eric | President & Immunovant CEO | Sell | 200K | $29.59 | $5.9M | 1.6M |
| 2026-04-20 | Venker Eric | President & Immunovant CEO | Exercise or conversion | 200K | $3.85 | $770K | 1.8M |
| 2026-04-20 | Pulik Richard | CFO | Grant | 61K | $0.00 | $0 | 298K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON50 Form 144 notices on file for ROIV worth $408.9M at the prices reported; 13 in the last 90 days worth $67.2M. Latest: Venker Eric filed on 2026-10-28 to sell 200,000 shares ($7.3M) from 2026-10-28.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-28 | Venker EricOfficer | 200K | $7.3M | 0.028% | 2026-10-28 | Rockefeller Financial LLC |
| 2026-10-20 | Venker EricOfficer | 200K | $7.0M | 0.028% | 2026-10-20 | Rockefeller Financial LLC |
| 2026-09-30 | Venker EricOfficer | 200K | $7.3M | 0.028% | 2026-09-30 | Rockefeller Financial LLC |
| 2026-09-15 | MEGHAN FITZGERALDOfficer | 5K | $210K | 0.001% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | MELISSA EPPERLYDirector | 23K | $931K | 0.003% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-08 | MEGHAN FITZGERALDDirector | 20K | $699K | 0.003% | 2026-09-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-28 | Venker EricOfficer | 200K | $7.1M | 0.028% | 2026-08-28 | Rockefeller Financial LLC |
| 2026-08-21 | MAYUKH SUKHATMEOfficer, Director | 145K | $5.3M | 0.020% | 2026-08-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-20 | MAYUKH SUKHATMEOfficer, Director | 18K | $653K | 0.002% | 2026-08-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-19 | MAYUKH SUKHATMEOfficer, Director | 173K | $6.4M | 0.024% | 2026-08-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-18 | MAYUKH SUKHATMEOfficer, Director | 137K | $5.0M | 0.019% | 2026-08-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | MAYUKH SUKHATMEOfficer, Director | 285K | $10.3M | 0.039% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-14 | MAYUKH SUKHATMEOfficer, Director | 243K | $8.8M | 0.034% | 2026-08-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-27 | Venker EricOfficer | 200K | $7.0M | 0.028% | 2026-07-27 | Rockefeller Financial LLC |
| 2026-06-30 | KEITH S MANCHESTERDirector | 200K | $7.1M | 0.028% | 2026-06-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-30 | MEGHAN FITZGERALDDirector | 10K | $347K | 0.001% | 2026-06-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | MELISSA EPPERLYDirector | 18K | $605K | 0.002% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | MAYUKH SUKHATMEOfficer, Director | 500K | $17.0M | 0.070% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-25 | MAYUKH SUKHATMEOfficer, Director | 500K | $17.1M | 0.070% | 2026-06-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-24 | Venker EricOfficer | 200K | $6.6M | 0.028% | 2026-06-24 | Rockefeller Financial LLC |
| 2026-05-22 | Venker EricOfficer | 200K | $6.1M | 0.028% | 2026-05-22 | Rockefeller Financial LLC |
| 2026-04-20 | Venker EricOfficer | 200K | $5.9M | 0.028% | 2026-04-20 | Rockefeller Financial LLC |
| 2026-04-16 | Gline MatthewOfficer | 290K | $8.4M | 0.040% | 2026-04-16 | Rockefeller Financial LLC |
| 2026-04-16 | Gline MatthewOfficer | 290K | $8.4M | 0.040% | 2026-04-16 | Rockefeller Financial LLC |
| 2026-04-08 | JENNIFER HUMESOfficer | 14K | $384K | 0.002% | 2026-04-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-17 | Venker EricOfficer | 200K | $5.6M | 0.028% | 2026-03-17 | Rockefeller Financial LLC |
| 2026-03-16 | MELISSA B EPPERLYDirector | 42K | $1.2M | 0.006% | 2026-03-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-20 | FRANK TORTIOfficer | 1.6M | $44.0M | 0.224% | 2026-02-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-19 | FRANK TORTIOfficer | 1.4M | $38.5M | 0.196% | 2026-02-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-13 | Venker EricOfficer | 200K | $5.3M | 0.028% | 2026-02-13 | Rockefeller Financial LLC |
| 2026-02-09 | Sukhatme MayukhOfficer | 339K | $9.0M | 0.047% | 2026-02-09 | Rockefeller Financial LLC |
| 2026-01-12 | Venker EricOfficer | 200K | $4.4M | 0.029% | 2026-01-12 | Rockefeller Financial LLC |
| 2025-12-31 | Sukhatme MayukhOfficer | 1.0M | $22.1M | 0.147% | 2025-12-31 | Rockefeller Financial LLC |
| 2025-12-29 | Sukhatme MayukhOfficer | 312K | $6.8M | 0.045% | 2025-12-29 | Rockefeller Financial LLC |
| 2025-12-29 | ERIC VENKEROfficer | 75K | $1.7M | 0.011% | 2025-12-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-29 | FRANK M TORTIOfficer, Director | 65K | $1.5M | 0.009% | 2025-12-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-23 | ERIC VENKEROfficer | 200K | $4.5M | 0.029% | 2025-12-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-23 | RICHARD PULIKOfficer | 260K | $5.8M | 0.037% | 2025-12-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-23 | RICHARD PULIK TRUSTOfficer | 147K | $3.3M | 0.021% | 2025-12-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-17 | Sukhatme MayukhOfficer | 27K | $619K | 0.004% | 2025-12-17 | Rockefeller Financial LLC |
| 2025-12-15 | Gline MatthewOfficer | 1.7M | $37.7M | 0.250% | 2025-12-15 | Rockefeller FinancialLLC |
| 2025-12-15 | Gline MatthewOfficer | 1.7M | $37.7M | 0.250% | 2025-12-15 | Rockefeller Financial LLC |
| 2025-12-09 | Venker EricOfficer | 200K | $4.2M | 0.029% | 2025-12-09 | Rockefeller Financial LLC |
| 2025-11-07 | Venker EricOfficer | 200K | $4.0M | 0.029% | 2025-11-07 | Rockefeller Financial LLC |
| 2025-10-17 | Venker EricOfficer | 118K | $2.0M | 0.017% | 2025-10-17 | Rockefeller Financial LLC |
| 2025-10-16 | Venker EricOfficer | 318K | $5.4M | 0.047% | 2025-10-16 | Rockefeller Financial LLC |
| 2025-10-15 | Venker EricOfficer | 415K | $7.0M | 0.061% | 2025-10-15 | Rockefeller Financial LLC |
| 2025-10-14 | Venker EricOfficer | 21K | $337K | 0.003% | 2025-10-13 | Rockefeller Financial LLC |
| 2025-10-09 | Venker EricOfficer | 105K | $1.7M | 0.015% | 2025-10-09 | Rockefeller Financial LLC |
| 2025-10-08 | Venker EricOfficer | 139K | $2.2M | 0.020% | 2025-10-08 | Rockefeller Financial LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of ROIV in their latest filing, all on Schedule 13G (passive). The largest reported stake is Abigail P. Johnson at 10.3% of the class (73,641,253 shares), filed 2026-03-06 for an event on 2026-02-27.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 59.3M | 8.2% | 2026-09-30 |
| 2026-08-13 | 13G/Ano. 3 | Morgan Stanleyparent holding company, corporation | 40.7M | 5.7% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 3 | Morgan Stanley Investment Management Inc.investment adviser, corporation | 39.4M | 5.5% | 2026-06-30 |
| 2026-05-06 | 13G/Ano. 7 | Ramaswamy Vivekindividual | 25.5M | 3.6% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-03-06 | 13G/Ano. 3 | Abigail P. Johnsonindividual | 73.6M | 10.3% | 2026-02-27 |
| 2026-03-06 | 13G/Ano. 3 | FMR LLCparent holding company | 73.6M | 10.3% | 2026-02-27 |
| 2026-02-17 | 13G/Ano. 5 | SB Investment Advisers (UK) Limitedcorporation | 16.4M | 2.3% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 5 | SoftBank Vision Fund L.P.partnership | 16.4M | 2.3% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 5 | SVF Holdings (UK) LLPpartnership | 16.4M | 2.3% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 5 | SVF Investments (UK) Limitedcorporation | 16.4M | 2.3% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 6 | VIKING GLOBAL INVESTORS LPpartnership | 23.6M | 3.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | HALVORSEN OLE ANDREASindividual | 23.6M | 3.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Ott David C.individual | 23.6M | 3.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Shabet Rose Sharonindividual | 23.6M | 3.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Viking Global Equities Master Ltd.corporation | 12.3M | 1.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | VIKING GLOBAL PERFORMANCE LLCother entity | 12.5M | 1.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Viking Global Opportunities GP LLCother entity | 6.2M | 0.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Viking Global Opportunities Illiquid Investments Sub-Master LPpartnership | 6.2M | 0.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Viking Global Opportunities Parent GP LLCother entity | 6.2M | 0.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Viking Global Opportunities Portfolio GP LLCother entity | 6.2M | 0.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Viking Long Fund Master Ltd.corporation | 4.9M | 0.7% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Viking Long Fund GP LLCother entity | 4.9M | 0.7% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Viking Global Equities II LPpartnership | 250K | 0.0% | 2025-09-30 |
13F holders
Tracked managers holding ROIV at their latest 13F. JSON9 of the 30 tracked managers held ROIV at their latest 13F, $1.02B in total at quarter-end prices. AQR Capital Management is the largest at $234.0M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 6.6M | $234.0M | 0.08% | +687K |
| Viking Global Investors | 2026-06-30 | 6.3M | $221.9M | 0.63% | -381K |
| Citadel Advisors | 2026-06-30 | 5.6M | $197.3M | 0.02% | +3.1M |
| Point72 Asset Management | 2026-06-30 | 4.5M | $158.3M | 0.17% | +3.6M |
| D. E. Shaw & Co. | 2026-06-30 | 3.0M | $105.2M | 0.05% | +1.6M |
| Greenlight Capital (DME Capital) | 2026-06-30 | 2.2M | $76.2M | 1.95% | 0 |
| Millennium Management | 2026-06-30 | 700K | $24.8M | 0.01% | -103K |
| Two Sigma Investments | 2026-06-30 | 22K | $779K | 0.00% | new |
| Fisher Asset Management | 2026-06-30 | 16K | $563K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q1 FY 2026 (quarter ended 2026-06-30) Roivant Sciences reported revenue of $1.4M, down 33.5% from the same quarter a year earlier, and net loss of $189.8M (-0.26 diluted EPS). In FY 2025 it generated -$750.3M of operating cash flow.
- Cash
- $1.25B
- Equity
- $4.23B
- Total assets
- $5.31B
- Shares outstanding
- 722,323,015
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q1 FY 2026 | 2026-06-30 | $1.4M | -$189.8M | -13164.8% | -0.26 |
| Q4 FY 2025derived | 2026-03-31 | $2.5M | $303.0M | 12023.6% | n/a |
| Q3 FY 2025 | 2025-12-31 | $2.0M | -$265.9M | -13301.2% | -0.38 |
| Q2 FY 2025 | 2025-09-30 | $1.6M | -$113.5M | -7225.9% | -0.17 |
| Q1 FY 2025 | 2025-06-30 | $2.2M | -$223.4M | -10292.9% | -0.33 |
| Q4 FY 2024derived | 2025-03-31 | $7.6M | -$206.5M | -2727.5% | n/a |
| Q3 FY 2024 | 2024-12-31 | $9.0M | $169.4M | 1878.3% | 0.23 |
| Q2 FY 2024 | 2024-09-30 | $4.5M | -$230.2M | -5143.8% | -0.31 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2026-03-31 | $8.3M | -$299.8M | -$750.3M | $8.2M | n/a | n/a |
| FY 2024 | 2025-03-31 | $29.1M | -$172.0M | -$839.5M | $4.6M | $1.29B | n/a |
| FY 2023 | 2024-03-31 | $32.7M | $4.35B | -$765.3M | $1.4M | $0 | n/a |
| FY 2022 | 2023-03-31 | $31.5M | -$1.01B | -$843.4M | $12.7M | $0 | n/a |
| FY 2021 | 2022-03-31 | $55.3M | -$845.3M | -$677.7M | $17.4M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Roivant Sciences in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Roivant Sciences (ROIV), SEC CIK 1635088, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-28.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-28.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-23.JSON and CSV
- Company record
- EDGAR filing index for CIK 1635088Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of ROIV is sold short?
40,302,998 shares were held short at the 2026-10-15 settlement, 7.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ROIV's daily short volume?
On 2026-10-28, 1,324,118 of the 1,638,949 ROIV shares reported to FINRA were sold short, 80.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ROIV have fails to deliver?
The SEC's latest file shows 719 ROIV shares failed to deliver at settlement 2026-09-28. Fails are reported per settlement date and published twice a month with a lag.
Are ROIV insiders buying or selling?
Insiders at ROIV reported 19 open-market sells worth $59.9M in the last 90 days and no open-market buys. Latest filing: MOMTAZEE JAMES C (Director) on 2026-10-23.
Have ROIV insiders filed to sell?
50 Form 144 notices on file for ROIV worth $408.9M at the prices reported; 13 in the last 90 days worth $67.2M. Latest: Venker Eric filed on 2026-10-28 to sell 200,000 shares ($7.3M) from 2026-10-28.
Who owns 5% or more of ROIV?
5 holders report 5% or more of ROIV in their latest filing, all on Schedule 13G (passive). The largest reported stake is Abigail P. Johnson at 10.3% of the class (73,641,253 shares), filed 2026-03-06 for an event on 2026-02-27.
What did ROIV report last quarter?
In Q1 FY 2026 (quarter ended 2026-06-30) Roivant Sciences reported revenue of $1.4M, down 33.5% from the same quarter a year earlier, and net loss of $189.8M (-0.26 diluted EPS). In FY 2025 it generated -$750.3M of operating cash flow.
Which tracked 13F managers own ROIV?
9 of the 30 tracked 13F managers held ROIV shares at their latest filing, $1.02B in all. The largest: Cliff Asness's AQR Capital Management (6.6M shares, $234.0M), Andreas Halvorsen's Viking Global Investors (6.3M shares, $221.9M), Ken Griffin's Citadel Advisors (5.6M shares, $197.3M), Steve Cohen's Point72 Asset Management (4.5M shares, $158.3M), D. E. Shaw & Co. (3.0M shares, $105.2M), David Einhorn's Greenlight Capital (DME Capital) (2.2M shares, $76.2M). The table above lists all 9.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.